Pliant Therapeutics Inc.
06/09/2025 | Press release | Distributed by Public on 06/09/2025 15:30
Proxy Results, Amendments to Bylaws (Form 8-K)
Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Pliant Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") on June 5, 2025. At the Annual Meeting, the stockholders of the Company approved an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company, as permitted by Delaware law (the "Amendment"), as further described in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 23, 2025 (the "Proxy Statement"). The Amendment became effective upon the filing of a Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation (the "Certificate of Amendment") with the Secretary of State of the State of Delaware on June 9, 2025.
The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, which is attached hereto as Exhibit 3.1 and incorporated by reference herein.
1
Item 5.07 Submission of Matters to a Vote of Security Holders.
As of April 9, 2025, the record date for the Annual Meeting, there were 61,386,278 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. The Company's stockholders voted on the following matters, which are described in detail in the Proxy Statement: (i) to elect John Curnutte, M.D., Ph.D., Katharine Knobil, M.D., and Thomas McCourt, as Class II directors of the Company to serve until the 2028 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal ("Proposal No. 1"), (ii) to approve, by non-binding advisory vote, the resolution approving the compensation of the Company's named executive officers ("Proposal No. 2"), (iii) to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by Delaware law ("Proposal No. 3"), and (iv) to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025 ("Proposal No. 4"). The vote results detailed below represent final results as certified by the Inspector of Elections.
Proposal No. 1:The Company's stockholders approved the election of each of the aforementioned Class II director nominees to serve until the 2028 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal. The voting results are as follows:
| Nominee | For | Withhold | ||||||
|
John Curnutte, M.D., Ph.D.
|
34,534,316 | 5,351,841 | ||||||
| Katharine Knobil, M.D. | 26,681,127 | 13,205,030 | ||||||
|
Thomas McCourt
|
31,557,399 | 8,328,758 | ||||||
The broker non-votes for Proposal No. 1 totaled 12,346,970 shares of common stock.
Proposal No. 2:The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers. The voting results are as follows:
| For | Against | Abstain | ||||||
| 30,037,373 | 8,937,835 | 910,949 | ||||||
The broker non-votes for Proposal No. 2 totaled 12,346,970 shares of common stock.
Proposal No. 3:As described in Item 5.03 above, the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by Delaware law. The voting results are as follows:
| For | Against | Abstain | ||||||
| 35,232,687 | 3,771,806 | 881,664 | ||||||
The broker non-votes for Proposal No. 3 totaled 12,346,970 shares of common stock.
Proposal No. 4:The Company's stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The voting results are as follows:
| For | Against | Abstain | ||||||
| 50,796,112 | 506,011 | 931,004 | ||||||
2
Pliant Therapeutics Inc. published this content on June 09, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 09, 2025 at 21:30 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io